Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-PEG3-FPN PET in Malignant Melanoma
NCT04747561Unknown
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of 18F-PFPN in melanoma. Primary endpoints: Sensitivity of 18F-PEG3-FPN PET/MR for diagnosis and staging in melanoma at 2 years and Specificity of 18F-PEG3-FPN PET/MR for diagnosis and staging in melanoma at 2 years. Status: unknown.
02
Drugs
18F-PFPN
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04747561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747561.